This resource was published on 10 November
PharmaLCA Software Infographic

PharmaLCA Software Infographic

Information & Guidance

This infographic provides an overview of PharmaLCA, highlighting the software's core objective, intended audience and key features.

This resource was published on 29 October
Data Collection Templates for PAS2090-compliant LCAs

Data Collection Templates for PAS2090-compliant LCAs

Template

This consolidated Excel workbook provides a standardised framework for collecting production-stage data for PAS 2090-compliant studies. The templates are intended to support both internal LCA activities and engagement with external partners, helping organisations align on data requirements, improve data quality, and make the data gathering and sharing process more efficient. The workbook can be used by any organisation conducting a PAS2090-compliant or aligned study, including pharmaceutical license holders, Contract (Development) Manufacturing Organisations, and raw material suppliers.

This resource was published on 17 September
Introductory Course to LCAs in the Pharmaceutical Sector

Introductory Course to LCAs in the Pharmaceutical Sector

Training Link

The health sector faces growing sustainability demands from regulators, payers, and consumers. A Life Cycle Assessment (LCA) helps quantify environmental impacts across a product’s lifecycle. This training will equip you with foundational LCA knowledge and practical insights for supplier engagement.​
​
A standard, called PAS 2090, aligning practices on LCA for pharmaceutical products was released in Q4 2025. PAS 2090 is used in this training to define specificities of LCA in the sector.​
​
In this training, we will​:

  1. Explain the Importance of LCAs in the pharmaceutical sector ​
  2. Understand the Fundamentals of LCAs​
  3. Analyze the Key Steps in Conducting an LCA​
  4. Discuss of the Role of Suppliers in Supporting LCA Practices​

The training was published by the Pharmaceutical Supply Chain Initiative (PSCI) and is available via their Learnster platform. Please note you have to register and log in to Learnster before you can access the course.

  • Life Cycle Assessment (LCA)
This resource was published on 13 April
Technical Guidance to PAS 2090:2025 - Version 1.1

Technical Guidance to PAS 2090:2025 - Version 1.1

Information & Guidance

The Pharma LCA Consortium, supported by its technical advisor Quantis, has developed a technical guidance document to accompany PAS 2090. This guidance aims to facilitate implementation by providing practical recommendations and illustrative examples. Version 1.1 has been issued to address identified discrepancies with PAS 2090, notably in relation to table referencing, and to improve overall clarity and alignment.

This resource was published on 28 January
Sustainable Healthcare Position Statement 2026
Unsplash, Margot Richard

Sustainable Healthcare Position Statement 2026

Report

A joint publication by the International Federation of Pharmaceutical Wholesalers and the Pharmaceutical Environment Group to align on GHG reporting and data sharing approaches between pharmaceutical companies and wholesalers.

  • GHG emissions
  • Climate Change
This resource was published on 1 December 2025
PAS 2090 infographic

PAS 2090 infographic

Information & Guidance

This infographic provides a visual overview of PAS 2090, outlining the standard's development process, core principles, intended audience and the key lifecycle stages it addresses.

This resource was published on 1 December 2025

Supplier FAQ on the PAS 2090

Document

This FAQ document is tailored for pharmaceutical suppliers and addresses common questions about PAS 2090, Life Cycle Assessments, available datasets and tools, and other practical considerations for implementation.

This resource was published on 15 March 2024
Abstract: a collaborative approach to develop Product Category Rules for pharmaceutical products

Abstract: a collaborative approach to develop Product Category Rules for pharmaceutical products

Report

This abstract describes the initial steps in an overarching programme to improve the measurement and reporting of environmental information for medicines. The technical work described is a key foundational element that will lead to the development of a universal, consensus-led standard for the benefit of the global healthcare systems, in its many forms, and ultimately for the improved health of patients and the environment in which they live.